On Friday, April 11, 2025, Cathie Wooden-led Ark Make investments executed notable trades, shedding shares in UiPath Inc. PATH, Prime Medication Inc. PRME, and Repare Therapeutics Inc. RPTX.
The PATH Commerce
Ark Make investments’s ARK Innovation ETF ARKK fund bought 4,256 shares of UiPath Inc. Primarily based on the closing worth of $10.87 on the day of the commerce, the overall worth of the transaction quantities to roughly $46,280.32.
UiPath’s inventory noticed a slight enhance of two.26% on the day.
The PRME Commerce
Prime Medication Inc. was one other firm that Ark Make investments determined to scale back its stake in. The ARKK fund bought 83,510 shares of PRME. With the inventory closing at $1.33 on the day of the commerce, the worth of the bought shares is round $111,068.30.
Apparently, PRME’s inventory skilled a big surge of 13.68% on the commerce day.
See Additionally: JPMorgan CEO Jamie Dimon Expects S&P 500 Progress Forecast To Be Reduce
The RPTX Commerce
Ark Make investments’s Ark Genomic Revolution ETF ARKG fund offloaded shares of Repare Therapeutics Inc. The fund bought 130,611 shares of RPTX. Given the closing worth of $0.9 on the commerce day, the overall worth of the transaction is roughly $117,549.90. The inventory’s worth remained unchanged on the day of the commerce.
These trades come within the wake of Ark Make investments’s earlier transactions, which featured outstanding purchases of Tempus AI Inc and Coinbase International Inc shares amid a pointy market selloff triggered by financial uncertainty and a 145% China tariff announcement by the Trump administration.
Learn Subsequent:
Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and printed by Benzinga editors.
Picture courtesy: Shutterstock
Inventory Rating Locked: Need to See it?
Benzinga Rankings provide you with important metrics on any inventory – anytime.
Reveal Full ScoreMarket Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
